TY - CHAP M1 - Book, Section TI - Chapter 158. Scleredema and Scleromyxedema A1 - Weenig, Roger H. A1 - Pittelkow, Mark R. A2 - Goldsmith, Lowell A. A2 - Katz, Stephen I. A2 - Gilchrest, Barbara A. A2 - Paller, Amy S. A2 - Leffell, David J. A2 - Wolff, Klaus PY - 2012 T2 - Fitzpatrick's Dermatology in General Medicine, 8e AB - Disorders characterized by excessive mucin deposition, increased collagen production, or fibrocyte hyperplasia are historically categorized as mucinoses, sclerosing disorders, and fibrosing disorders, respectively. The fibroblast is central in each of these conditions. Thus, shifting our focus from the fibroblast product (mucin, collagen, and fibrosis) to the cell of origin, the fibroblast and the mechanisms that stimulate specific fibroblast activities will provide better understanding of the histopathogenesis of these diseases and also lays a foundation for the development of more effective treatments for these incapacitating conditions. In some disorders, a singular fibroblast activity predominates, such as excessive mucin or collagen production [pretibial myxedema (see Chapter 151) and sclerodermoid disorders respectively (see Chapter 157)]. In others, a combination of excessive mucin and collagen production is observed (scleredema) or excessive mucin production and fibroblast hyperplasia occurs [scleromyxedema and nephrogenic systemic fibrosis (see Chapter 150)]. SN - PB - The McGraw-Hill Companies CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=56077301 ER -